Phase 2 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with advanced kidney disease, meaning their kidneys are working at less than 20% of normal capacity and they are not yet on dialysis, OR people who started dialysis (either hemodialysis or peritoneal dialysis) within the last 6 months. (Note: for people who started dialysis after a sudden kidney crisis and were not previously seen in a kidney clinic, at least 90 days of dialysis may be required before joining — confirm details with the trial site.)
- People who also have at least one of the following: an enlarged heart muscle (detected by imaging); a hospital stay for heart failure or a heart or blood vessel condition in the last 12 months; type 2 diabetes; or a high level of protein in their urine (this last condition does not apply to dialysis patients who produce less than 500 ml of urine per day).
Who may not be able to join:
- People with type 1 diabetes.
- People with a history of a serious condition called euglycemic ketoacidosis (a dangerous chemical imbalance in the blood, which can occur even when blood sugar is normal).
- People with a known allergic reaction or sensitivity to a class of medications called SGLT-2 inhibitors.
- People whose heart and circulation are currently unstable and require intravenous medications to keep the heart pumping.
- People with a resting systolic blood pressure below 90 mmHg (very low blood pressure).
- People with severe liver scarring (advanced cirrhosis, known medically as Child-Pugh class C).
- People with active liver inflammation, indicated by significantly elevated liver blood test results.
- People who have recurring serious infections of the genitals or urinary tract.
- People currently taking certain medications (digoxin, phenobarbital, phenytoin, rifampin, or ritonavir) that cannot be safely stopped, due to potential interactions with the trial drug.
- People who have metal-containing cardiac devices implanted in their body (such as certain pacemakers or defibrillators) that are not safe for MRI scanning.
- People with claustrophobia (fear of enclosed spaces), as the trial involves MRI scans.
- People with cochlear implants (hearing devices implanted in the ear).
- People with metal fragments or objects in or around their eyes.
- People who are pregnant or breastfeeding.
- People with any other medical condition that the trial doctor considers a reason not to participate.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Thomas Mavrakanas, MD, Research Institute of the McGill University Health Center
Phone: 514-934-1934
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in left ventricular mass to volume ratio (LVMV) from baseline to 12 months, as assessed by cardiac MRI compared with placebo
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.